SPRC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 121286 min ago

@ $3.99

Išleistas: 6 vas. 2024 @ 16:45

Grąža: -64.91%

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	193 780
Vidutinė apimtis	833 000
Rinkos kapitalizacija	3.43M
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0130 (0.93%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: -0.10 (neutral)

Signal:(53.164) Neutral

SciSparc Ltd. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MXIM	0.937
HYMC	0.83
LSBK	0.801

10 Labiausiai neigiamai susiję koreliacijos
IKNX	-0.851
APOP	-0.841
CMLF	-0.826
MAGS	-0.805
MOSY	-0.804

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

SciSparc Ltd. Koreliacija - Valiuta/Žaliavos

-0.14
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.03
( neutral )

-0.70
( moderate negative )

0.20
( neutral )

SciSparc Ltd. Finansinės ataskaitos

Annual	2023
Pajamos:	$2.88M
Bruto pelnas:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2023
Pajamos:	$2.88M
Bruto pelnas:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2022
Pajamos:	$1.35M
Bruto pelnas:	$1.03M (76.10 %)
EPS:	$-14.73

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.